Massachusetts 2025-2026 Regular Session

Massachusetts Senate Bill S909

Introduced
2/27/25  

Caption

Empowering patients and entrepreneurs with real transparency on cost

Impact

The implementation of this bill is expected to have significant implications for state healthcare laws. By improving access to quality data on healthcare costs, the bill aims to promote competition among healthcare providers and encourage sustainable pricing practices. This could result in lower costs for patients and greater accountability from providers regarding their billing practices. Additionally, this effort aligns with broader national trends toward transparency in healthcare, which have been proven beneficial in other jurisdictions that have adopted similar measures.

Summary

Senate Bill 909 aims to enhance transparency in the healthcare system by empowering patients and entrepreneurs through the release of critical cost data. The legislation seeks to amend Chapter 12C of the Massachusetts General Laws to ensure that the state's healthcare center annually releases comprehensive data on hospital payment and utilization. Specifically, it mandates the release of information regarding the 100 most common inpatient stays, outpatient procedures, and drugs to allow a better understanding of healthcare costs across the state. By providing this data to the public, the bill is intended to enable consumers to make more informed choices regarding their healthcare services and associated costs.

Contention

While the bill generally resonates with patient advocacy groups and those in favor of greater healthcare transparency, it may encounter opposition from certain healthcare providers and insurers concerned about how the release of such data could affect their business models and pricing structures. There are concerns that the data could be misinterpreted or misused by consumers unfamiliar with the complexities of medical billing. As the public discussion surrounding SB 909 progresses, it will be critical for lawmakers to address these potential pitfalls to ensure that the intended benefits of increased transparency are realized.

Companion Bills

No companion bills found.

Previously Filed As

MA S807

Empowering patients and entrepreneurs with real transparency on cost

MA H945

To ensure prescription drug cost transparency and affordability

MA S3012

Relative to pharmaceutical access, costs and transparency

MA S749

Relative to pharmaceutical access, costs and transparency

MA S2492

Relative to pharmaceutical access, costs and transparency

MA S2520

Relative to pharmaceutical access, costs and transparency

MA S732

Relative to promoting comprehensive transparency in the pharmaceutical industry

MA H1176

Relative to promoting comprehensive transparency in the pharmaceutical industry

MA S2499

Relative to pharmaceutical access, costs and transparency

MA S783

To promote transparency and prevent price gouging of pharmaceutical drug prices

Similar Bills

No similar bills found.